

Nanovectors could improve the combined administration of antimalarial drugs

According to the study, the strategy has the added advantage of targeting the transmissible phase of the parasite- the gametocyte

Barcelona, August 8, 2019-. Encapsulating two drugs with different properties into nanovesicles surrounded by antibodies can greatly improve their delivery and efficacy, according to [a study](#) led by **Xavier Fernández Busquets**, director of the joint Nanomalaria unit at the [Institute for Bionengineering of Catalonia \(IBEC\)](#) and the [Barcelona Institute for Global Health \(ISGlobal\)](#), an institution supported by "la Caixa".

Combining two drugs that act through different mechanisms is one of the most efficient approaches currently used to treat malaria. However, differences in the drugs' physicochemical properties (solubility, half-life, etc.) often **affect treatment efficacy**.

To overcome this obstacle, Fernández Busquets and his team have developed a nanovector –consisting of small spheres or liposomes– that can **simultaneously transport compounds that are soluble in water** (hydrophilic) **and in lipids** (lipophilic).

"By encapsulating both drugs in the same nanovector, we make sure that both will persist for the same time in the organism," explains Fernández-Busquets. As proof of concept, the research team introduced the water-soluble drug pyronaridine in the liposome lumen and the lipid-soluble drug atovaquone in its membrane. In addition, they covered the liposome with an antibody that recognises a protein expressed by red blood cells (whether they are infected or not) and gametocytes (the sexual phase of the parasite, responsible for host-to-host transmission). Hence the term immunoliposome.

The results show that both drugs, when encapsulated, **inhibited parasite growth *in vitro*** at concentrations that had no effect when used as free drugs. Thanks to the antibodies, **the liposomes rapidly bound to the target cells and efficiently delivered the drug**.

The authors argue that this strategy could be used in a near future to treat severe cases of malaria that are admitted in hospitals, where intravenous administration of liposomes is feasible. The challenge lies in developing nanovectors adequate for oral administration in order to treat non-complicated malaria, a line of work the research group is currently exploring.

"Current treatments target mostly the asexual phases of the parasite. This new strategy would also target the sexual phase or gametocyte, the only phase that can be transmitted from humans to mosquitoes, and would thereby contribute to reducing the emergence and spread of antimalarial resistance," adds the researcher.

Reference

Biosca A, Dirscherl L, Moles E, Imperial S, Fernàndez-Busquets X. An ImmunoPEGLiposome for Targeted Antimalarial Combination Therapy at the Nanoscale. *Pharmaceutics*. 2019 Jul 16;11(7). pii: E341. [doi: 10.3390/pharmaceutics11070341](https://doi.org/10.3390/pharmaceutics11070341).

About ISGlobal

The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between "la Caixa" and academic and government institutions to contribute to the efforts undertaken by the international community to address the challenges in global health. ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. The pivotal mechanism of its work model is the transfer of knowledge generated by scientific research to practice, a task undertaken by the institute's Education and Policy and Global Development departments. ISGlobal a member of the CERCA programme of the Generalitat de Catalunya.

ISGlobal's Press Office

Marta Solano
marta.solano@isglobal.org
93 214 73 33 / 661 45 16 00

Carolina Pozo
Carolina.pozo@isglobal.org
0034 93 214 73 33

A partnership of:

